| CAS No.: | 1270138-40-3 |
|---|---|
| Formula: | C22h30n4o |
| EINECS: | Nsi-189 |
| Type: | Pharmaceutical Intermediates |
| Appearance: | Powder |
| Quality: | Industrial |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Detailed Product Information
Product Name: NSI-189 Base
Trade Name: NSA-189
CAS No.: 1270138-40-3
Molecular Formula: C22H30N40
Molecular Weight: 366.5g/mol
Purity: 99% HPLC
Appearance: White Powder
Typical use: Nootropics
Standard Packing: 100gram,1kg,25kg
Shelf Life: 2 years
Storage: Room temperature away from light
Description:
NSI-189 is an experimental neurogenic compound that may potentially treat MDD, traumatic brain injury, stroke, cognition problems, mental disorders, post-traumatic stress disorder, and neurodegenerative disease due to aging.
Neuralstem Inc is a biopharmaceutical company that develops NSI-189. The chemical is being investigated as an alternative drug designed for patients who failed to respond to conventional medications.
In 2011, 41 volunteers completed the phase I clinical trials. Following this was the phase IB trial in 2012 and 2014, which focused on treating patients with MDD.
However, the phase II clinical trial was not as successful as phase I. It failed to meet the requirements for the primary effectiveness endpoint in MDD [R].
At present, NSI189 is still being tested for other conditions such as improved brain health, diabetic neuropathy, stroke, neurodegenerative disease, post-traumatic stress disorder, and Angelman syndrome. It is used to treat traumatic brain injury.
The FDA has granted NSI-189 Orphan Drug Designation as a treatment for the rare disease, Angelman syndrome.
Product Benefits:
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}